Abstract
This review summarizes recent progress in understanding the role of p53-upregulated mediator of apoptosis (PUMA) in molecular pathways with respect to its potential therapeutic applications. Particular emphasis is given to the PUMA´s role in ionizing radiation-induced signalling as radiotoxicity of normal tissue is mediated mostly via apoptosis. PUMA and its p53-dependent and p53- independent induction are described and potential use as a new target for the development of radioprotective agents is suggested. Further implications, including targeting PUMA to prevent and treat cardiovascular and neurodegenerative diseases, are also discussed together with an overview of other therapeutic applications. Finally, basic chemical structures for the development of novel PUMA modulators such as pifithrine derivatives, kinase inhibitors or modulators of Bcl-2 protein family are described.
Keywords: PUMA, ionizing radiation, small molecule inhibitor, radioprotection, hearth, brain.
Current Drug Targets
Title:New Light on An Old Friend: Targeting PUMA in Radioprotection and Therapy of Cardiovascular and Neurodegenerative Diseases
Volume: 19 Issue: 16
Author(s): Ales Tichy, Jan Marek, Radim Havelek*, Jaroslav Pejchal, Martina Seifrtova, Lenka Zarybnicka, Alzbeta Filipova, Martina Rezacova and Zuzana Sinkorova
Affiliation:
- Department of Medical Biochemistry, Faculty of Medicine in Hradec Kralove, Charles University, 500 03 Hradec Kralove,Czech Republic
Keywords: PUMA, ionizing radiation, small molecule inhibitor, radioprotection, hearth, brain.
Abstract: This review summarizes recent progress in understanding the role of p53-upregulated mediator of apoptosis (PUMA) in molecular pathways with respect to its potential therapeutic applications. Particular emphasis is given to the PUMA´s role in ionizing radiation-induced signalling as radiotoxicity of normal tissue is mediated mostly via apoptosis. PUMA and its p53-dependent and p53- independent induction are described and potential use as a new target for the development of radioprotective agents is suggested. Further implications, including targeting PUMA to prevent and treat cardiovascular and neurodegenerative diseases, are also discussed together with an overview of other therapeutic applications. Finally, basic chemical structures for the development of novel PUMA modulators such as pifithrine derivatives, kinase inhibitors or modulators of Bcl-2 protein family are described.
Export Options
About this article
Cite this article as:
Tichy Ales , Marek Jan, Havelek Radim *, Pejchal Jaroslav , Seifrtova Martina , Zarybnicka Lenka , Filipova Alzbeta , Rezacova Martina and Sinkorova Zuzana , New Light on An Old Friend: Targeting PUMA in Radioprotection and Therapy of Cardiovascular and Neurodegenerative Diseases, Current Drug Targets 2018; 19 (16) . https://dx.doi.org/10.2174/1389450119666180406110743
DOI https://dx.doi.org/10.2174/1389450119666180406110743 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-Angiogenic Peptides for Cancer Therapeutics
Current Pharmaceutical Biotechnology The Ubiquitin-Proteasome System (UPS) and the Mechanism of Action of Bortezomib
Current Pharmaceutical Design Role of Caspases, Bax and Bcl-2 in Chrysin-Induced Apoptosis in the A549 Human Lung Adenocarcinoma Epithelial Cells
Anti-Cancer Agents in Medicinal Chemistry Herpes Simplex Virus Vectors for the Nervous System
Current Gene Therapy Identification of Key mRNAs, miRNAs, and mRNA-miRNA Network Involved in Papillary Thyroid Carcinoma
Current Bioinformatics Design and Endpoints of Clinical and Translational Trials in Advanced Colorectal Cancer. A Proposal from GROUP Español Multidisciplinar en Cancer Digestivo (GEMCAD)
Reviews on Recent Clinical Trials Recent Patents of microRNAs as Biomarkers for Breast, Leukemia, Prostate and Cervical Cancers
Recent Patents on Biomarkers A Descriptive Analysis of Post-Chemotherapy Development of Interstitial Lung Disease Using Spontaneous Reporting Data in Japan
Current Drug Safety Structure, Function, and Pathogenesis of SHP2 in Developmental Disorders and Tumorigenesis
Current Cancer Drug Targets Critical microRNAs in Lung Cancer: Recent Advances and Potential Applications
Anti-Cancer Agents in Medicinal Chemistry ErbB Targeted Drugs and Angiogenesis
Current Vascular Pharmacology Ellipticine, its Derivatives: Re-evaluation of Clinical Suitability with the Aid of Drug Delivery Systems
Current Cancer Drug Targets Prodigiosins as Anti Cancer Agents: Living Upto Their Name
Current Pharmaceutical Design Targeted and Armed Oncolytic Poxviruses for Cancer: the Lead Example of JX-594
Current Pharmaceutical Biotechnology Retinoic Acid and Iron Metabolism: A Step Towards Design of a Novel Antitubercular Drug
Current Pharmaceutical Biotechnology Histone Deacetylase Inhibitors as Potential Therapeutic Agents for the Treatment of Malignant Mesothelioma
Anti-Cancer Agents in Medicinal Chemistry The Offer of Chemistry to Targeted Therapy in Cancer
Recent Patents on Biotechnology Implications of the Dominant Role of Transporters in Drug Uptake by Cells
Current Topics in Medicinal Chemistry Some Implications of Receptor Kinase Signaling Pathway for Development of Multitargeted Kinase Inhibitors
Current Radiopharmaceuticals Design of Lipophilic Prodrugs to Improve Drug Delivery and Efficacy
Current Drug Targets